leadf
logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharma 'confident' following completion of ArtemiC Phase II COVID-19 trial

MGC Pharmaceuticals Ltd's (ASX:MXC) (OTCMKTS:MGCLF) (FRA:MGC) Roby Zomer caught up with Proactive's Andrew Scott following completion of its 50-patient Phase II double-blind, placebo-controlled clinical trial for anti-inflammatory treatment, ArtemiC, on patients diagnosed with COVID-19. Final results are expected to be published next month.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.088 AUD

ASX:MXC
Market: ASX
Market Cap: $196.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharmaceuticals get set for LSE debut as first medicinal cannabis...

MGC Pharmaceuticals Ltd's (ASX:MXC) (FRA:H5O) (LON:MXC) Co-founder and MD Roby Zomer joins Proactive London to explain why the company has chosen to list on the London Stock Exchange (LSE) on Tuesday, February 9.  This move will mean the firm will become the first medicinal cannabis...

3 weeks ago

2 min read